Skip to product information
1 of 1

GeneBio Systems

Recombinant Human CD16b/FCGR3B Protein (aa 1-200, His Tag)

Recombinant Human CD16b/FCGR3B Protein (aa 1-200, His Tag)

SKU:PKSH031291

Regular price $1,224.00 CAD
Regular price Sale price $1,224.00 CAD
Sale Sold out
Shipping calculated at checkout.

Size: 100μg

Storage: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months.

Shipping: This product is provided as lyophilized powder which is shipped with ice packs.

Exp date: 12 months

Category ID_II: Recombinant Proteins

Category ID_III: Others

Abbreviation:

Target Synonym: CD16b and FCGR6B;FCG3;FCGR3;FCRIII;FCRIIIb;Fc-gamma RIII-beta;FcR-10;IgG Fc receptor III-1;Low affinity immunoglobulin gamma Fc region receptor III-B

Research Areas: immunology

Conjugation:

Target Species: Human

Expression Host: HEK293 Cells

Application:

Fusion tag: C-His

UNIProt ID: O75015

Accession: NP_000561.3

Background: The asialoglycoprotein receptor (ASGPR), an endocytotic cell surface receptor expressed by hepatocytes, is triggered by triantennary binding to galactose residues of macromolecules such as asialoorosomucoid (ASOR). ASGPR belongs to the long-form subfamily of the C-type/Ca2+ dependent lectin family. It is a complex of two noncovalently-linked and highly homologous subunits, a major 42 kDa glycoprotein ASGPR1(MHL-1) and a minor 51 kDa glycoprotein ASGR2 (MHL-2). ASGPR1 is synthesized as a type II transmembrane protein that contains a cytosolic N-terminal domain, a single transmembrane segment, and an extracellular domain which contains two important structural regions. The first is a stalk domain that contributes to noncovalent oligomerization, and the second is a Ca2+-dependent carbohydrate binding domain at the very C-terminus that is unusually stabilized by three ions. The research regarded that ASGPR1 could be targeted for anti- hepatitis B virus (HBV) drug development.

Concentration:

Activity: Not validated for activity

Sequence: Met 1-Ser 200

Purity: > 95 % as determined by reducing SDS-PAGE.

Formulation: Lyophilized from sterile PBS, pH 7.4
Normally 5% - 8% trehalose, mannitol and 0.01% Tween 80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the printed manual.

Reconstitution: Please refer to the printed manual for detailed information.

Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method.

Calculated MW: 22.2 kDa

ObservedMW: 50-55 kDa

View full details